Merck has received FDA approval for a subcutaneous formulation of its leading cancer immunotherapy, Keytruda. This new administration method offers improved patient convenience over intravenous delivery and is expected to help maintain Keytruda's market dominance as biosimilar competition grows. The approval builds on extensive clinical trial data demonstrating comparable efficacy and safety to the established intravenous formulation, underscoring Merck’s commitment to innovation in oncology.